Simplify Logo

Full-Time

Scientist – Functional Genomics

Confirmed live in the last 24 hours

Calico Labs

Calico Labs

201-500 employees

Research and develop treatments for aging

Biotechnology
Healthcare

Compensation Overview

$127k - $135kAnnually

+ Bonus

Senior, Expert

San Bruno, CA, USA

Must work onsite five days per week.

Category
Genomics
Biology & Biotech
Required Skills
Python
R
Requirements
  • Ph.D. in Genomics, Genetics, Molecular Biology, Systems Biology, or a closely related field
  • Strong record of originality and productivity as evidenced by impactful publications
  • Proficient in bulk and single cell *seq technologies (e.g. RNA, ATAC, ChIP, Ribo, CITE)
  • Experienced in large-scale genomic perturbation screens (CRISPR-Cas9, shRNA, etc.)
  • Strong bioinformatics skills with experience analyzing genomic data using R and/or Python
  • Must be willing to work onsite five days per week

Calico Labs focuses on researching the biology of aging and creating treatments for diseases related to aging. The company conducts scientific research to understand how aging works and what causes age-related diseases. It collaborates with academic institutions and other biopharmaceutical companies to enhance its research efforts. Calico Labs uses advanced technologies and encourages teamwork among scientists from different fields to speed up the discovery of new medical treatments. The company earns money through partnerships, joint research projects, and grants, which help fund its work. The main goal of Calico Labs is to make important advancements in understanding aging and to develop effective therapies for age-related conditions.

Company Stage

Seed

Total Funding

$2M

Headquarters

South San Francisco, California

Founded

2013

Growth & Insights
Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • The inclusion of fosigotifator in the FDA's START Pilot Program highlights Calico Labs' potential to develop groundbreaking treatments for rare diseases.
  • Extending the collaboration with the Broad Institute until 2029 ensures continued progress in understanding aging and developing therapies for age-related neurodegeneration.
  • The appointment of renowned experts like Michael Lenardo, M.D., as Chief Scientific Officer strengthens Calico Labs' leadership and scientific expertise.

What critics are saying

  • The highly specialized focus on aging and age-related diseases may limit the company's market opportunities compared to broader biopharmaceutical firms.
  • Dependence on strategic partnerships and collaborations could pose risks if these alliances face challenges or dissolve.

What makes Calico Labs unique

  • Calico Labs focuses exclusively on the biology of aging and age-related diseases, setting it apart from other biopharmaceutical companies with broader research scopes.
  • Their strategic partnerships with leading academic institutions and biopharmaceutical firms, such as the Broad Institute and AbbVie, enhance their research capabilities and accelerate innovation.
  • Calico Labs' emphasis on interdisciplinary collaboration and advanced technologies fosters a unique research environment that drives significant scientific discoveries.